CN115336743A - Application of Ha Louba dew oral liquid in preparation of anti-alcohol product - Google Patents
Application of Ha Louba dew oral liquid in preparation of anti-alcohol product Download PDFInfo
- Publication number
- CN115336743A CN115336743A CN202210996700.5A CN202210996700A CN115336743A CN 115336743 A CN115336743 A CN 115336743A CN 202210996700 A CN202210996700 A CN 202210996700A CN 115336743 A CN115336743 A CN 115336743A
- Authority
- CN
- China
- Prior art keywords
- oral liquid
- extract
- alcohol
- product
- liver
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000007788 liquid Substances 0.000 title claims abstract description 52
- 238000002360 preparation method Methods 0.000 title claims abstract description 12
- 230000002075 anti-alcohol Effects 0.000 title claims abstract description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 84
- 239000000284 extract Substances 0.000 claims abstract description 29
- 239000000203 mixture Substances 0.000 claims abstract description 18
- 208000007848 Alcoholism Diseases 0.000 claims abstract description 17
- 201000007930 alcohol dependence Diseases 0.000 claims abstract description 17
- 241000272503 Sparassis radicata Species 0.000 claims abstract description 15
- 230000001154 acute effect Effects 0.000 claims abstract description 13
- 240000000588 Hericium erinaceus Species 0.000 claims abstract description 10
- 235000007328 Hericium erinaceus Nutrition 0.000 claims abstract description 10
- 241000233866 Fungi Species 0.000 claims abstract description 8
- 240000000599 Lentinula edodes Species 0.000 claims abstract description 8
- 235000013305 food Nutrition 0.000 claims abstract description 8
- 239000003814 drug Substances 0.000 claims abstract description 7
- 230000036541 health Effects 0.000 claims abstract description 7
- 230000006870 function Effects 0.000 claims abstract description 5
- 206010019133 Hangover Diseases 0.000 claims abstract description 4
- 206010067125 Liver injury Diseases 0.000 claims description 21
- FYGDTMLNYKFZSV-URKRLVJHSA-N (2s,3r,4s,5s,6r)-2-[(2r,4r,5r,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5r,6s)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1[C@@H](CO)O[C@@H](OC2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-URKRLVJHSA-N 0.000 claims description 10
- 229920002498 Beta-glucan Polymers 0.000 claims description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 10
- 150000004676 glycans Chemical class 0.000 claims description 9
- 231100000234 hepatic damage Toxicity 0.000 claims description 9
- 231100000753 hepatic injury Toxicity 0.000 claims description 9
- 230000008818 liver damage Effects 0.000 claims description 9
- 229920001282 polysaccharide Polymers 0.000 claims description 9
- 239000005017 polysaccharide Substances 0.000 claims description 9
- 238000001035 drying Methods 0.000 claims description 8
- 108010073178 Glucan 1,4-alpha-Glucosidase Proteins 0.000 claims description 5
- 108091005804 Peptidases Proteins 0.000 claims description 5
- 239000004365 Protease Substances 0.000 claims description 5
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims description 5
- 102000004139 alpha-Amylases Human genes 0.000 claims description 5
- 108090000637 alpha-Amylases Proteins 0.000 claims description 5
- 229940024171 alpha-amylase Drugs 0.000 claims description 5
- 238000000605 extraction Methods 0.000 claims description 5
- 239000000843 powder Substances 0.000 claims description 5
- 230000001376 precipitating effect Effects 0.000 claims description 5
- 229920000310 Alpha glucan Polymers 0.000 claims description 4
- 238000000227 grinding Methods 0.000 claims description 4
- 238000010438 heat treatment Methods 0.000 claims description 4
- 235000015097 nutrients Nutrition 0.000 claims description 4
- 102000004169 proteins and genes Human genes 0.000 claims description 4
- 108090000623 proteins and genes Proteins 0.000 claims description 4
- 238000000926 separation method Methods 0.000 claims description 4
- 238000012545 processing Methods 0.000 claims description 3
- 238000005119 centrifugation Methods 0.000 claims description 2
- 230000000593 degrading effect Effects 0.000 claims description 2
- 238000002156 mixing Methods 0.000 claims description 2
- 241000699670 Mus sp. Species 0.000 abstract description 31
- 210000004185 liver Anatomy 0.000 abstract description 23
- 240000008187 Erythrina edulis Species 0.000 abstract description 8
- 235000002757 Erythrina edulis Nutrition 0.000 abstract description 8
- 230000004060 metabolic process Effects 0.000 abstract description 8
- 230000003647 oxidation Effects 0.000 abstract description 7
- 238000007254 oxidation reaction Methods 0.000 abstract description 7
- 230000002708 enhancing effect Effects 0.000 abstract description 6
- 235000001715 Lentinula edodes Nutrition 0.000 abstract description 4
- 230000000694 effects Effects 0.000 description 52
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 21
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 21
- 210000004369 blood Anatomy 0.000 description 19
- 239000008280 blood Substances 0.000 description 19
- 241000699666 Mus <mouse, genus> Species 0.000 description 18
- 108010081577 aldehyde dehydrogenase (NAD(P)+) Proteins 0.000 description 18
- 102000007698 Alcohol dehydrogenase Human genes 0.000 description 16
- 108010021809 Alcohol dehydrogenase Proteins 0.000 description 16
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 16
- 102000019197 Superoxide Dismutase Human genes 0.000 description 15
- 108010012715 Superoxide dismutase Proteins 0.000 description 15
- 229940118019 malondialdehyde Drugs 0.000 description 15
- 210000002966 serum Anatomy 0.000 description 14
- 239000000047 product Substances 0.000 description 13
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 10
- 210000005228 liver tissue Anatomy 0.000 description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 210000005229 liver cell Anatomy 0.000 description 6
- 230000028527 righting reflex Effects 0.000 description 6
- 241000221377 Auricularia Species 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 229940088598 enzyme Drugs 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 230000003859 lipid peroxidation Effects 0.000 description 5
- 239000003963 antioxidant agent Substances 0.000 description 4
- 230000003078 antioxidant effect Effects 0.000 description 4
- 235000006708 antioxidants Nutrition 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 206010036067 polydipsia Diseases 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 230000035987 intoxication Effects 0.000 description 3
- 231100000566 intoxication Toxicity 0.000 description 3
- 230000036542 oxidative stress Effects 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 239000003642 reactive oxygen metabolite Substances 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 101710088194 Dehydrogenase Proteins 0.000 description 2
- 102000003929 Transaminases Human genes 0.000 description 2
- 108090000340 Transaminases Proteins 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 231100000439 acute liver injury Toxicity 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000008034 disappearance Effects 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- HHEAADYXPMHMCT-UHFFFAOYSA-N dpph Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1[N]N(C=1C=CC=CC=1)C1=CC=CC=C1 HHEAADYXPMHMCT-UHFFFAOYSA-N 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 210000003470 mitochondria Anatomy 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 230000000050 nutritive effect Effects 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 1
- 241000221454 Auriculariaceae Species 0.000 description 1
- 238000011725 BALB/c mouse Methods 0.000 description 1
- 101000821485 Branchiostoma lanceolatum Sarcoplasmic calcium-binding proteins II, V, VI, and VII Proteins 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 241000252212 Danio rerio Species 0.000 description 1
- 241000545017 Harpagus Species 0.000 description 1
- 206010019663 Hepatic failure Diseases 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 206010019728 Hepatitis alcoholic Diseases 0.000 description 1
- 206010019837 Hepatocellular injury Diseases 0.000 description 1
- 229920001491 Lentinan Polymers 0.000 description 1
- 241000282376 Panthera tigris Species 0.000 description 1
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 1
- 241000222383 Polyporales Species 0.000 description 1
- 241000555745 Sciuridae Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 241000123261 Sparassidaceae Species 0.000 description 1
- 241000123241 Sparassis Species 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 241000009791 Tremellomycetes Species 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 208000002353 alcoholic hepatitis Diseases 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 230000003090 exacerbative effect Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 230000002443 hepatoprotective effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 229940115286 lentinan Drugs 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 235000015073 liquid stocks Nutrition 0.000 description 1
- 231100000849 liver cell damage Toxicity 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000005976 liver dysfunction Effects 0.000 description 1
- 231100000835 liver failure Toxicity 0.000 description 1
- 208000007903 liver failure Diseases 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 208000018191 liver inflammation Diseases 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 description 1
- 229960000282 metronidazole Drugs 0.000 description 1
- 230000010016 myocardial function Effects 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229960005141 piperazine Drugs 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 150000003628 tricarboxylic acids Chemical class 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L31/00—Edible extracts or preparations of fungi; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/10—Preparation or pretreatment of starting material
- A61K2236/19—Preparation or pretreatment of starting material involving fermentation using yeast, bacteria or both; enzymatic treatment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Nutrition Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Epidemiology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses an application of a Haru dew oral liquid in preparation of an anti-alcohol product. The haru banu oral liquid is applied to preparing an anti-alcohol product. The anti-hangover product comprises at least one of food, medicine and health product. The composition is applied to preparing a product for relieving alcoholism; the composition comprises a sparassis crispa extract, a lentinus edodes extract, a hericium erinaceus extract and a black fungus extract in a mass ratio of 40. The Hulu balu oral liquid has good functions of relieving alcoholism and protecting liver for acute alcoholism mice, and is related to accelerating alcohol metabolism and enhancing the oxidation resistance of organisms.
Description
Technical Field
The invention belongs to the field of new application of food, and particularly relates to application of a haru balu oral liquid in preparation of an anti-alcohol product.
Background
According to the report of the world health organization, drinking is one of the main causes of more than 60 diseases. Statistically, 90% of alcoholics exhibit hepatic steatosis and 35% develop alcoholic hepatitis. Alcohol and its metabolite acetaldehyde both cause damage to liver cells, resulting in liver inflammation. Prolonged excessive drinking can lead to chronic inflammation of the liver, further exacerbating liver damage and dysfunction, and ultimately leading to liver failure.
Acute alcoholism is a central nervous disorder caused by excessive alcohol intake at one time, has important influence on global morbidity and mortality, and seriously harms human health. Research shows that the liver is the main site of alcohol metabolism, and ingested alcohol is absorbed into the blood through the gastrointestinal tract, so that the alcohol content in the blood is increased, and then the alcohol is conveyed to the liver for metabolic clearance. ADH and ALDH are key enzymes of alcohol metabolism in vivo, and are mainly present in the cytoplasm and mitochondria of hepatocytes. The alcohol taken in is firstly metabolized into acetaldehyde by ADH, then the acetaldehyde is further oxidized into acetic acid by ALDH, and finally the acetic acid is completely oxidized into water and carbon dioxide to be discharged out of the body by tricarboxylic acid circulation. Acetaldehyde is a main metabolite of ethanol, has strong lipid peroxidation and toxicity, is particularly obvious in damage to liver, can cause reduction of liver function and myocardial function, and can cause accumulation of ethanol and acetaldehyde in liver cells and accelerate damage of the liver cells due to reduction of ADH and ALDH activity. When the liver is damaged by alcohol, the change of serum enzymes in the liver is most obvious as the change of transaminase, AST is a sensitive index of liver damage, and the AST enzyme activity in serum is one of important indexes for evaluating acute liver damage. AST plays an important role in the synthesis and catabolism of amino acids, and in normal cases, the AST content in blood is very low, so the activity of AST in serum is generally low, but when liver damage caused by alcohol damages mitochondria in liver cells, the AST activity is enhanced, and the permeability of liver cell membranes is increased, resulting in the release of a large amount of AST into blood. Numerous studies have shown that alcohol-induced liver damage is closely related to oxidative stress and lipid peroxidation. When the ingested alcohol exceeds the self-metabolism capability of the liver, the liver can be promoted to generate a large amount of Reactive Oxygen Species (ROS), so that the balance of an oxidation system in the body is damaged, meanwhile, the ROS is excessively accumulated in the body to cause lipid peroxidation, so that the MDA content is increased, the consumption of an antioxidant substance SOD which can remove free radicals is accelerated, the SOD activity is reduced, and the liver injury is caused. Therefore, the MDA content and SOD activity in liver tissues can reflect the degree of liver injury.
Ha Louba oral liquid is the leading one of Baiquan Xianghu trade company, and is a human body nutrition supplement produced in Korea through years of research and development, and mainly comprises sparassis crispa extract, and is compounded with shiitake mushroom, hericium erinaceus, black fungus extract and the like. At present, the deep processing products mainly comprising sparassis crispa in the world are few. Sparassis crispa (Sparasis crispa) belongs to Basidiomycotina, heterobasidiomycetes, aphyllophorales, sparassidaceae, sparassis. The sparassis crispa sporocarp contains 39.3-43.6% of polysaccharide. The Sparassis crispa has high nutritional and health-care values, researches show that the Sparassis crispa polysaccharide has the highest clearance rates of 75%, 80% and 30% for DPPH, OH and O-2 free radicals respectively in the range of 0.25-4 mg/mL, and the absorbance of reducing force is 0.18. The clearance rates of Sparassis crispa polysaccharide SCP-II on DPPH, OH and O-2 free radicals are 85.63%, 85.36% and 40.86%, respectively, and the reduction force absorbance is 0.38. The Sparassis crispa mycelium polysaccharide can resist the oxidation effect in the body of transgenic zebra fish treated by metronidazole, has antioxidant capacity, and the antioxidant capacity of 150 microgram/mL polysaccharide is equivalent to that of 100 microgram/mL vitamin C. The mushroom, the hericium erinaceus and the black fungus are all medicine and food homologous substances, have rich nutritive value and edible value and have various pharmacological effects. Lentinan has antioxidant capacity. Hericium erinaceus is a fungus used as both medicine and food, and has high nutritive value. Auricularia is fruiting body of Auricularia of Auriculariaceae, modern pharmacological studies show that: auricularia has various pharmacological effects of resisting oxidation, replenishing blood, lowering blood sugar, regulating blood lipid, and enhancing immunity.
Disclosure of Invention
The invention aims to provide application of Haru balu oral liquid in preparation of an anti-alcohol product. The Hulu balu oral liquid has good functions of relieving alcoholism and protecting liver for acute alcoholism mice, and is related to accelerating alcohol metabolism and enhancing the oxidation resistance of organisms.
The invention provides application of Haru balu oral liquid in preparation of an anti-alcohol product.
In the application, the anti-alcohol product comprises at least one of food, medicine and health care products.
The haru dew oral liquid of the invention is applied to the preparation of any one of the following functional products:
1) Reducing liver damage caused by alcohol;
2) Improving liver injury caused by acute alcohol.
In the above application, the product comprises at least one of food, medicine and health care product.
The invention also provides the application of the extract of the composition in preparing an anti-inebriation product;
the extract of the composition comprises the following components in percentage by mass of 40.
In the above application, the preparation method of the extract of the composition comprises the following steps: grinding the Sparassis crispa, the shiitake mushrooms, the hericium erinaceus and the black fungus into powder, mixing the powder with water, heating and extracting, then carrying out centrifugal separation to extract supernatant, adding ethanol with the mass percentage of 80% to precipitate polysaccharide, and drying to obtain a hot extract; and carrying out enzymolysis on the hot extract, and then precipitating with ethanol to obtain the extract of the composition.
In the above application, the heating and extracting conditions are as follows: 110-130 ℃ for 2.5-4 hours;
the conditions of the centrifugation were as follows: centrifugal separation is carried out for 15-30 minutes at 8000rpm and 4 ℃;
the drying conditions were as follows: drying for 10-15 hours at 50-60 ℃;
and after the thermal extraction, carrying out enzymolysis on a beta-glucan sample subjected to hydrothermal extraction by using alpha-amylase (English name alpha-amylase), protease (English name protease) and amyloglucosidase (English name amyloglucosidase), degrading alpha-glucan and protein except the beta-glucan, precipitating by using ethanol, and recovering the non-enzymolyzed beta-glucan and other nutrients for processing.
In the invention, the preparation method of the extract of the composition specifically comprises the following steps: grinding 100 g of Sparassis crispa, hericium erinaceus, auricularia and Lentinus Edodes into powder, adding 5L of water, and extracting with hot water at 121 deg.C for 3 hr; centrifuging at 8000rpm and 4 deg.C for 20 min, recovering supernatant, adding 80% ethanol to precipitate polysaccharide, and drying at 55 deg.C for 12 hr to obtain extract of the composition; subjecting the hydrothermal extract to enzymolysis with alpha-amylase, protease, amyloglucosi-dase to degrade alpha-glucan and protein other than beta-glucan, precipitating with ethanol, and recovering non-enzymolyzed beta-glucan and other nutrients.
The invention further provides an application of the composition in preparing a product with any one of the following functions:
1) Reducing liver damage caused by alcohol;
2) Improving liver injury caused by acute alcohol;
the composition comprises a sparassis crispa extract, a lentinus edodes extract, a hericium erinaceus extract and a black fungus extract in a mass ratio of 40.
The invention has the following beneficial effects:
compared with a model group, a compound extracting solution (Sparassis crispa, shiitake mushroom, hericium erinaceus and black fungus extracts) product group (0.25 g/kg) can obviously prolong the drunkenness incubation period of a mouse, each dose group of the Haruba oral liquid can reduce the blood alcohol concentration and the activity of glutamic oxalacetic transaminase of a rat, a high dose group (5.56 g/kg) of the Haruba oral liquid can obviously reduce the content of malondialdehyde in the liver, the activity of ethanol dehydrogenase is improved, a medium dose group (2.78 g/kg) can obviously reduce the content of malondialdehyde in the liver, and the activities of acetaldehyde dehydrogenase, ethanol dehydrogenase and superoxide dismutase are obviously increased. The low dose group (1.39 g/kg) can obviously reduce the content of malonaldehyde and increase the activity of acetaldehyde dehydrogenase. In conclusion, the haru dew oral liquid has better effects of relieving alcoholism and protecting liver on mice suffering from acute alcoholism, and is related to accelerating alcohol metabolism and enhancing the oxidation resistance of organisms.
Drawings
FIG. 1 shows the effect of the Halu barlow oral liquid on the content of ethanol in mouse serum and the activity of AST.
FIG. 2 shows the effect of HALUBALU oral liquid on MDA activity in liver tissue of mice.
FIG. 3 shows the effect of the Halulubau oral liquid on ALDH activity in liver tissue of mice.
FIG. 4 is a graph showing the effect of the Halufab oral liquid of the present invention on ADH activity in liver tissue of mice.
FIG. 5 shows the effect of Hailubau oral liquid on SOD activity in mouse liver tissue.
Detailed Description
The experimental procedures used in the following examples are all conventional procedures unless otherwise specified.
Materials, reagents and the like used in the following examples are commercially available unless otherwise specified.
Example 1 test of the Jilu Baru oral liquid for relieving alcoholism
1. Experimental Material
1.1 reagents and reagents
ADH kit (Nanjing institute for bioengineering, lot number 20201228), ALDH kit (Nanjing institute for bioengineering, lot number 20201228), MDA kit (Nanjing institute for bioengineering, lot number 20201230), SOD kit (Nanjing institute for bioengineering, lot number 20201230), AST kit (Nanjing institute for bioengineering, lot number 20201229), and blood ethanol kit (Nanjing institute for bioengineering, lot number 20210104).
1.2 instruments and devices
Multifunctional micropore detector (Synergy H1), high speed refrigerated centrifuge (Multifuge X1R) electronic balance (BSA 224S-CW).
1.3 animals
SPF-grade BALB/c mice 78, male, 6 weeks old, body weight 20. + -.2 g, supplied by Stephen Bei Fu (Beijing) Biotechnology Ltd, laboratory animal production license number: SYXK Beijing 2019-0010. The experimental preposed animal is adapted to the environment of a laboratory for 3 days at the room temperature of 20-25 ℃, is fed by the standard pellet feed and freely drinks water.
2. Experimental method
2.1 pharmaceutical formulation
Ha Louba dew oral liquid each specification is 20g/18ml (Baiquan tiger trade company, inc.).
Ha Louba dew high dose group: ha Louba dew oral liquid stock solution with concentration of 1.11g/ml
Ha Lou bar lotion in dose group: 20ml of the high dose group was taken and diluted to 40ml with distilled water to a concentration of 0.56g/ml.
Ha Lou barlu low dose group: 20ml of the middle dose group is taken, and the middle dose group is diluted to 40ml by distilled water, wherein the concentration is 0.28g/ml.
The administration volume of each group is 5ml/kg, namely, the administration dose of each group is 5.56g/kg of high dose, 2.78g/kg of medium dose and 1.39g/kg of low dose.
2.2 antialcoholism test
2.2.1 establishment and grouping of mouse intoxication models
78 mice were divided into a Hallowra oral liquid high dose group (5.56 g/kg), a Ha Louba oral liquid medium dose group (2.78 g/kg), a Ha Louba oral liquid low dose group (1.39 g/kg), a model control group and a blank group at random according to body weight, and 13 mice were selected. Except for the model control group and the blank group, each group was gavaged 1 time per day for 14 days at the corresponding dose, and the model control group and the blank group were given the same volume of physiological saline. After 30min of administration on day 14, each mouse was gavaged with 15ml/kg of 56 ° red star Erguotou per mouse, based on body weight.
2.2.2 effects of Ha Louba oral liquid on drunken mice's drunkenness latency and drunkenness time
And (3) after the mice are subjected to last administration for 30min, the mice are subjected to intragastric administration by liquor according to the alcohol dose of 15mL/kg body weight, and drunk mice are obtained (whether the mice are drunk or not is based on whether the righting reflex disappears, the mice are placed in a squirrel cage with the back facing downwards after intragastric administration, and if the posture of the mice with the back facing downwards is kept for more than 30s, the righting reflex disappears, namely drunk). After mice which die immediately after gastric lavage and are not drunk for more than 3 hours are eliminated, the drunk latency (the time from the drunk to the disappearance of the righting reflex) and the drunk time (the time from the disappearance of the righting reflex to the recovery of the righting reflex) of each group of mice are observed and recorded, and the drunk latency and the drunk time (the judgment standard of the resuscitation of the mice is that the drunk mice recover from the righting reflex and move freely Mao Huashun) of each group of mice are compared.
2.2.3 effects of Ha Louba oral liquid on blood alcohol concentration and activity of aspartate Aminotransferase (AST) in drunken mice
After the mice are perfused with white spirit for 5 hours, the eyeballs of the mice are picked to take blood, serum is separated, and the ethanol content and the activity of the aspartate Aminotransferase (AST) in the serum of the mice are measured according to the blood ethanol kit and the AST kit.
2.2.4.4 effects of Ha Louba dew on biochemical indicators of liver part of drunken mice
After blood is taken, a mouse is killed by adopting a cervical dislocation method, the liver is taken, filter paper is used for completely absorbing the surface moisture and the blood of the liver, then, 10% (mass fraction) of homogenate is prepared by using 9 times of normal saline, the homogenate is centrifuged for 15min (3 000r/min) at 4 ℃, and the supernatant is taken and the content of Malondialdehyde (MDA), alcohol Dehydrogenase (ADH), acetaldehyde dehydrogenase (ALDH) and superoxide dismutase (SOD) in the liver is measured according to the instruction of a kit.
2.2.5 statistical analysis
GraphPad Prism 5.0 statistical software was used, data are expressed as mean. + -. Standard deviation, and comparisons between groups were by t-test. Compared with the control group, P <0.05 indicates significant difference, P <0.01 indicates very significant difference, and P >0.05 indicates no significant difference.
3. Results of the experiment
3.1 influence of Ha Louba dew oral liquid on mouse drunkenness latency and sobering-up time
TABLE 1 influence of Haru Barlow oral liquid on the intoxication latency and time of mice
Table 1 results show that the high and low dose groups of haru baru oral liquid significantly prolonged the intoxication latency of mice (P < 0.05) compared to the model group.
3.2 Ha Louba dew oral liquid influence on ethanol content in serum and AST activity
TABLE 2 influence of Harubau oral liquid on mouse serum ethanol and AST enzyme activities
Note: compared to the blank group, # P <0.05, # P <0.01; compared with the model group, P <0.05, P <0.01, one-time excessive drinking resulted in a sharp increase in blood alcohol content, and the results in fig. 1 and table 2 show that:
(1) Compared with the blank group, the model group remarkably improves the ethanol content in the serum of the mouse (P < 0.01), and the successful construction of the acute alcoholism model of the mouse is shown. Compared with a model group, the harpagu oral liquid can obviously reduce the ethanol content in serum (P is less than 0.01) in high, medium and low dose groups (5.56 g/kg, 2.78g/kg and 1.39 g/kg).
(2) Compared with a blank group, the AST enzyme activity in the serum of the model group mouse is obviously improved (P is less than 0.01), which indicates that the liver of the acute alcoholism mouse is damaged. Compared with a model group, the Harlubalu oral liquid can obviously reduce AST enzyme activity (P is less than 0.01) in the serum of a mouse in each dose group. The Ha Louba dew oral liquid has the effect of resisting AST (acute liver injury) abnormally increased in mice with acute liver injury caused by excessive drinking, and the Ha Louba dew oral liquid is proved to be capable of effectively relieving liver cell damage caused by excessive drinking, protecting liver cell membranes and reducing release of intracellular enzymes.
3.3 Effect of Ha Louba dew oral liquid on MDA, ALDH, ADH, SOD Activity in liver tissue
TABLE 3 influence of Harlu Barlu oral liquid on MDA, ALDH, ADH, SOD content of mouse liver
Elevated MDA levels and reduced SOD levels are important indicators of oxidative stress in the liver. The results in table 3 and fig. 2-5 show that compared with the blank group, the model group can increase the MDA content in the liver tissue of the mouse (P < 0.01), reduce the ADH enzyme activity in the liver tissue of the mouse (P < 0.05), and the ALDH enzyme activity and the SOD enzyme activity have no statistical difference. Compared with a model group, the high, medium and low dose groups (5.56 g/kg, 2.78g/kg and 1.39 g/kg) of the Haru balu oral liquid can obviously reduce the MDA content (P is less than 0.05), and the medium dose group (2.78 g/kg) can obviously increase the SOD enzyme activity (P is less than 0.01). The Harlu balu oral liquid can improve SOD activity to a certain extent and has the functions of eliminating oxygen free radicals and reducing MDA activity.
ADH and ALDH are key enzymes of alcohol metabolism, and the concentration of ethanol in blood is affected by changes in its activity. Compared with a model group, the Harubalu oral liquid high-dose group (5.56 g/kg) can obviously improve the activity of ADH enzyme (p is less than 0.05). The middle dose group (2.78 g/kg) can obviously increase the activity of ADH and ALDH enzymes (P is less than 0.01, and P is less than 0.05). The ALDH enzyme activity can be obviously increased by a low-dose group (1.39 g/kg) (P is less than 0.01). The results show that Ha Louba dew oral liquid can accelerate alcohol metabolism by enhancing ADH and ALDH activity, thereby reducing the concentration of ethanol in blood.
4. Results
Through the above experiment, it can be seen that:
(1) The results show that compared with a model group, the harubau oral liquid pretreatment can obviously reduce the blood alcohol content of the mice suffering from acute alcoholism and improve the activity of ADH and ALDH enzymes in liver tissues of the mice. The Ha Louba oral liquid can improve the activity of ADH and ALDH enzymes, accelerate alcohol metabolism, reduce the content of blood alcohol and have a certain effect of relieving alcoholism.
(2) In the invention, compared with the normal group, the AST in the serum of the model group is obviously increased, and the Hallowba oral liquid can obviously reduce the AST in the serum of the mouse, which shows that the Ha Louba aqua oral liquid can reduce the liver injury caused by alcohol.
(3) The results of the invention show that the Haru balu oral liquid can obviously reduce the MDA content in liver tissues, and can improve the liver SOD activity of mice. The Ha Louba oral liquid can improve the liver damage caused by acute alcohol by enhancing the body oxidation resistance and inhibiting lipid peroxidation.
In conclusion, the Haru babu oral liquid has good effects of relieving alcoholism and protecting liver, can improve drunkenness and liver injury caused by ethanol, has an alcoholism relieving mechanism related to the enhancement of alcohol metabolic enzyme activity, and can improve liver injury by inhibiting oxidative stress and lipid peroxidation. Therefore, the harubau oral liquid can obviously relieve acute alcoholism caused by ethanol.
EXAMPLE 2 anti-hangover and hepatoprotective effects of extracts of a composition
The preparation method of the extract of the composition specifically comprises the following steps: grinding 100 g of Sparassis crispa, hericium erinaceus, auricularia and Lentinus Edodes into powder, adding 5L of water, and extracting with hot water at 121 deg.C for 3 hr; centrifuging at 8000rpm and 4 deg.C for 20 min, recovering supernatant, adding 80% ethanol to precipitate polysaccharide, and drying at 55 deg.C for 12 hr to obtain extract of the composition; subjecting the hydrothermal extract to enzymolysis with alpha-amylase, protease, amyloglucosi-dase to degrade alpha-glucan and protein other than beta-glucan, precipitating with ethanol, and recovering non-enzymolyzed beta-glucan and other nutrients.
Experiments prove that the extract of the composition has the same liver protection effect with Ha Louba dew oral liquid.
Claims (8)
1. Ha Louba oral liquid, and its application in preparing hangover relieving product.
2. Use according to claim 1, characterized in that: the anti-hangover product comprises at least one of food, medicine and health product.
3. Ha Louba dew oral liquid is applied to preparation of products with any one of the following functions:
1) Reducing liver damage caused by alcohol;
2) Improving liver injury caused by acute alcohol.
4. Use according to claim 3, characterized in that: the product comprises at least one of food, medicine and health care product.
5. The application of the extract of a composition in preparing a product for relieving alcoholism;
the extract of the composition comprises the following components in percentage by mass of 40.
6. Use according to claim 5, characterized in that: the preparation method of the extract of the composition comprises the following steps: grinding the Sparassis crispa, the shiitake mushroom, the hericium erinaceus and the black fungus into powder, mixing with water, heating and extracting, then carrying out centrifugal separation to extract supernate, adding 80% ethanol by mass to precipitate polysaccharide, and drying to obtain the extract of the composition.
7. Use according to claim 6, characterized in that: the heating extraction conditions are as follows: 110-130 ℃ for 2.5-4 hours;
the conditions of the centrifugation were as follows: centrifugal separation is carried out for 15-30 minutes at 8000rpm and 4 ℃;
the drying conditions were as follows: drying for 10-15 hours at 50-60 ℃;
and after the thermal extraction, carrying out enzymolysis on a beta-glucan sample subjected to the hydrothermal extraction by using alpha-amylase, protease and amyloglucosidase, degrading alpha-glucan and protein except the beta-glucan, then precipitating by using ethanol, and recovering non-enzymolyzed beta-glucan and other nutrients for processing.
8. Use according to any one of claims 5 to 7, characterized in that: the anti-alcohol product comprises any one of the following functional products:
1) Reducing liver damage caused by alcohol;
2) Improving liver injury caused by acute alcohol.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210996700.5A CN115336743A (en) | 2022-08-19 | 2022-08-19 | Application of Ha Louba dew oral liquid in preparation of anti-alcohol product |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210996700.5A CN115336743A (en) | 2022-08-19 | 2022-08-19 | Application of Ha Louba dew oral liquid in preparation of anti-alcohol product |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN115336743A true CN115336743A (en) | 2022-11-15 |
Family
ID=83954661
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210996700.5A Pending CN115336743A (en) | 2022-08-19 | 2022-08-19 | Application of Ha Louba dew oral liquid in preparation of anti-alcohol product |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN115336743A (en) |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101112396A (en) * | 2006-07-24 | 2008-01-30 | 中岛三博 | Extract of sparassis crispa MH-3 bacterial strain and method for preparing the same and use thereof |
| CN101889679A (en) * | 2009-05-20 | 2010-11-24 | 凌沛学 | Composition with disintoxicating and liver-protecting effects and application thereof in food and health-care food |
| CN108497118A (en) * | 2018-04-11 | 2018-09-07 | 广州汝丽多食品科技有限公司 | A kind of sobering-up health tea and preparation method thereof |
| CN111956736A (en) * | 2020-08-04 | 2020-11-20 | 浙江省农业科学院 | Hypoglycemic composition mainly comprising sparassis crispa as well as preparation method and application thereof |
| CN112843101A (en) * | 2019-11-26 | 2021-05-28 | 北京大学 | Application of Thelephora ganbajun zang in protecting liver injury |
| CN114588175A (en) * | 2022-04-22 | 2022-06-07 | 吉林农业大学 | Application of black fungus dietary fiber in alcoholic liver injury |
-
2022
- 2022-08-19 CN CN202210996700.5A patent/CN115336743A/en active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101112396A (en) * | 2006-07-24 | 2008-01-30 | 中岛三博 | Extract of sparassis crispa MH-3 bacterial strain and method for preparing the same and use thereof |
| CN101889679A (en) * | 2009-05-20 | 2010-11-24 | 凌沛学 | Composition with disintoxicating and liver-protecting effects and application thereof in food and health-care food |
| CN108497118A (en) * | 2018-04-11 | 2018-09-07 | 广州汝丽多食品科技有限公司 | A kind of sobering-up health tea and preparation method thereof |
| CN112843101A (en) * | 2019-11-26 | 2021-05-28 | 北京大学 | Application of Thelephora ganbajun zang in protecting liver injury |
| CN111956736A (en) * | 2020-08-04 | 2020-11-20 | 浙江省农业科学院 | Hypoglycemic composition mainly comprising sparassis crispa as well as preparation method and application thereof |
| CN114588175A (en) * | 2022-04-22 | 2022-06-07 | 吉林农业大学 | Application of black fungus dietary fiber in alcoholic liver injury |
Non-Patent Citations (2)
| Title |
|---|
| 哈露巴露: "来自纯天然食品哈露巴露的自述", pages 1 - 9, Retrieved from the Internet <URL:https://mp.weixin.qq.com/s?__biz=Mzg4NDUzMDY4Mw==&mid=2247483957&idx=1&sn=df45490f72f21ede547cd0760a577589&chksm=cfb78ea1f8c007b77f1db2f9685154f3c040666aba3e4ff75a9dd20253f47c95f7c235c75eb3&scene=21#wechat_redirect> * |
| 哈露巴露: "高度美酒的新拍档！", pages 104 - 4, Retrieved from the Internet <URL:https://mp.weixin.qq.com/s/o9_MF9dxAkTaqqAiQqLdjg> * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN106620640B (en) | Composition for dispelling effects of alcohol and protecting liver as well as preparation method and application thereof | |
| CN113712205B (en) | Oyster peptide powder composition and preparation method and application thereof | |
| KR100787633B1 (en) | Tea and Tea Manufacturing Method for Improving Liver Function and Curing of Hangover | |
| CN107951935A (en) | A kind of pueraria lobata hoveniae semoveniae semen broken wall composition and its preparation method and application | |
| WO2020052074A1 (en) | Extract for improving liver detoxification, dispelling alcohol and protecting liver, and preparation method therefor | |
| CN101664180B (en) | Health-care nutritional complexing agent with health effect and preparation method thereof | |
| CN107691944A (en) | A kind of high activity crocodile peptide albumen compound beverage and preparation method thereof | |
| CN112979748B (en) | Active peptide with effect of preventing chronic alcoholic liver injury | |
| CN111418850B (en) | Composition for relieving alcoholism and protecting liver and preparation method thereof | |
| CN115336743A (en) | Application of Ha Louba dew oral liquid in preparation of anti-alcohol product | |
| WO2009084875A2 (en) | Composition for preventing and treating metabolic diseases comprising the extract of lysimachiae foenum-graeci herba | |
| CN110302316A (en) | A kind of relieving alcoholism and protecting liver oral solution and preparation method | |
| CN110074392A (en) | A kind of Antialcoholic liver-protecting nourishing the stomach shield intestines composition and preparation method thereof | |
| CN106727902B (en) | Cordyceps sinensis-containing traditional Chinese medicine composition for dispelling effects of alcohol and protecting liver and application thereof | |
| CN109601802A (en) | A kind of health beverages composition and the preparation method and application thereof for preventing and/or treating gout | |
| CN111066994A (en) | Functional beverage for dispelling effects of alcohol and protecting liver and preparation method thereof | |
| CN114514973B (en) | Preparation method of radix puerariae compound fermented beverage with sobering and liver protecting effects | |
| CN115975063A (en) | Morchella polysaccharide, preparation method and application | |
| WO2020052073A1 (en) | Extract for promoting lipid metabolism in liver, resisting inflammation and reducing enzyme content, and preparation method therefor | |
| CN112007092A (en) | Anti-alcohol composition and preparation method thereof | |
| CN107604032B (en) | Camel blood polypeptide with anti-fatigue effect and preparation method thereof | |
| KR101999383B1 (en) | Pharmaceutical Composition for Improving, Protecting or Treating Alcoholic Liver Disease comprising Capsosiphon fulvescens Extract as Active Ingredient | |
| CN116473239B (en) | Protein peptide composition for relieving acute alcoholic liver injury and preparation method thereof | |
| CN115282217B (en) | Hypolipidemic and liver-protecting function of cinerea fermented tea | |
| CN117815365A (en) | Composition for preventing and treating intestinal diseases and oxidative stress and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |